GlassScriptPhysician profile
Fiza Tariq
NPI 1487264438
$394.28
in general payments reported to CMS, 2019-2025
11 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.82 · 2022: $65.35 · 2023: $64.55 · 2024: $142 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286 · Entertainment: $22.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.10 |
| Entertainment | $22.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $65.41 | 2024 | Radius |
| Genzyme Corporation | $56.28 | 2022-2025 | |
| Abbvie INC. | $52.21 | 2024 | |
| Dompe US, INC. | $43.13 | 2022-2024 | Oxervate |
| Samsara Vision | $42.54 | 2023 | |
| Alcon Vision LLC | $29.63 | 2025 | Tryptyr |
| Harrow Eye, LLC | $25.50 | 2025 | Vevye |
| Optos, INC. | $22.01 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.82 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.65 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $18.10 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fiza Tariq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.